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Early Discharge After Primary Percutaneous Coronary Intervention:
The Added Value of N-Terminal Pro–Brain Natriuretic Peptide to the
Zwolle Risk Score
Dirk A. A. M. Schellings, MD; Ahmet Adiyaman, MD, PhD; Evangelos Giannitsis, MD, PhD; Christian Hamm, MD, PhD;
Harry Suryapranata, MD, PhD; Jurrien M. ten Berg, MD, PhD; Jan C. A. Hoorntje, MD, PhD; Arnoud W. J. van ‘t Hof, MD, PhD
Background-—The Zwolle Risk Score (ZRS) identiﬁes ST-elevation myocardial infarction (STEMI) patients treated with primary
percutaneous coronary intervention (PPCI) eligible for early discharge. We aimed to investigate whether baseline N-terminal pro–
brain natriuretic peptide (NT-proBNP) is also able to identify these patients and could improve future risk strategies.
Methods and Results-—PPCI patients included in the Ongoing Tiroﬁban in Myocardial Infarction Evaluation (On-TIME) II study were
candidates (N=861). We analyzed whether ZRS and baseline NT-proBNP predicted 30-day mortality and assessed the occurrence
of major adverse cardiac events (MACEs) and major bleeding. Receiver operating characteristic curve analysis was used to assess
discriminative accuracy for ZRS, NT-pro-BNP, and their combination. After multiple imputation, 845 patients were included. Both
ZRS >3 (hazard ratio [HR]=9.42; P<0.001) and log NT-pro-BNP (HR=2.61; P<0.001) values were associated with 30-day mortality.
On multivariate analysis, both the ZRS (HR=1.41; 95% conﬁdence interval [CI]=1.27 to 1.56; P<0.001) and log NT-proBNP
(HR=2.09; 95% CI=1.59 to 2.74; P<0.001) independently predicted death at 30 days. The area under the curve for 30-day mortality
for combined ZRS/NT-proBNP was 0.94 (95% CI=0.90 to 0.99), with optimal predictive values of a ZRS ≥2 and a NT-proBNP value
of ≥200 pg/mL. Using these cut-off values, 64% of the study population could be identiﬁed as very low risk with zero mortality at
30 days follow-up and low occurrence of MACEs and major bleeding between 48 hours and 10 days (1.3% and 0.6%, respectively).
Conclusion-—Baseline NT-proBNP identiﬁes a large group of low-risk patients who may be eligible for early (48- to 72-hour)
discharge, whereas optimal predictive accuracy is reached by the combination of both baseline NT-proBNP and ZRS. ( J Am Heart
Assoc. 2014;3:e001089 doi: 10.1161/JAHA.114.001089)
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I n low-risk patients with ST-elevation myocardial infarction(STEMI), treated with primary percutaneous coronary
intervention (PPCI), early discharge has been proven to be
safe and feasible with good cost-effectiveness.1–6
In order to identify PPCI patients eligible for early
discharge, the Zwolle Risk Score (ZRS) has been developed.
This validated score, assessed by a point system, was able
to identify a large group of patients at low mortality risk
who could be discharged between 48 and 72 hours after
PPCI.7
For several years, the biomarkers BNP and N-terminal pro–
brain natriuretic peptide (NT-proBNP) have been frequently
used, especially in the diagnosis and prognosis of heart failure
(HF). Interestingly, these biomarkers also predict major
adverse cardiac events (MACEs) and mortality both early
and late after ST elevation and acute non-STEMI.8–14
We studied whether baseline NT-proBNP levels could
identify PPCI patients at low risk who may be eligible for
early discharge above and beyond the ZRS.
Methods
Patients
Our population consists of patients with diagnosis of STEMI
admitted for PPCI who were included in the Ongoing Tiroﬁban
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in Myocardial Infarction Evaluation (On-TIME) II trial,15 a
prospective, multicenter, placebo-controlled, randomized, clin-
ical trial. The rationale, design, and primary results of On-
TIME II have been previously described.15,16 The trial is
registered under No. ISRCTN06195297.
Brieﬂy, enrollment was from June 2006 to November 2007.
Eligible patients were 21 to 85 years of age with symptoms of
acute myocardial infarction (MI) of more than 30 minutes, but
less than 24 hours, and ST-segment elevation of more than
1 mV in 2 adjacent ECG leads.
Exclusion criteria were severe renal dysfunction (glomer-
ular ﬁltration rate (GFR) <30 mL/min or serum creat-
inine >200 mmol/L) (>2.5 mg/dL), therapy-resistant
cardiogenic shock (systolic blood pressure [SBP] ≤80
mm Hg for >30 minutes), persistent severe hypertension
(HTN; SBP >180 mm Hg or diastolic blood pressure
>110 mm Hg), or a contraindication to anticoagulation or
increased risk of bleeding. Also, patients with a left bundle
branch block, pregnant and/or breastfeeding women, and
patients with a life expectancy of less than 1 year were
excluded. From each patient, a written informed consent for
participation in both the On-TIME II study and future data
analysis was obtained. The study protocol was approved by




All patients were planned to undergo PPCI and were initially
treated according to the On-TIME II study protocol and
randomly assigned to (prehospital) treatment with tiroﬁban
(25 lg/kg bolus and 0.15 lg kg1 min1 maintenance infu-
sion for 18 hours) or placebo. PPCI was performed with
standard techniques if the coronary anatomy was suitable for
angioplasty. Additional treatment with stents and devices was
to the discretion of the treating cardiologist. All patients were
treated with optimal drug therapy, including angiotensin-
converting enzyme inhibitors, b-blockers, aspirin, and a statin.
Final discharge and admission duration was to the discretion
of the treating cardiologist, irrespective of NT-proBNP values
or ZRS.
Measurements
NT-proBNP plasma levels were measured (Roche, Central
Hematology Laboratory, University of Heidelberg, Heidelberg,
Germany) in each patient on admission, after sheath insertion
before PPCI was performed. For each patient, the ZRS was
calculated. This score, assessed by a point system, has shown
to be able to identify a large group of patients at very low risk
who may safely be discharged early after PPCI.7 Very-low-risk
patients are those with a score ≤3 (mortality rate of 0.1% at
2 days and 0.2% between 2 and 10 days; Figure 1).
Endpoints
The primary endpoint in this study was death from any cause at
30 days. Secondary endpoints were nonfatal MACEs andmajor
bleeding until 10 days after admission as well as potentially
lethal events that would interfere with the patients’ eligibility for
early (between 48 and 72 hours) and safe discharge.MACEwas
deﬁned as recurrent myocardial infarction (RMI), urgent target
vessel revascularization, and malignant cardiac arrhythmias
(ventricular tachycardia [VT] or ventricular ﬁbrillation [VF])
occurring later than 24 hours after PPCI.
RMI was deﬁned as a new increase of creatine kinase
(CK)/myocardial band that was 3 or more times the upper
limit of normal, present in 2 different blood samples and
accompanied by chest pain or ECG changes. VT (sustained or
nonsustained) was deﬁned as a sequence of 3 or more
ventricular beats, with a frequency >100 beats per minute
and was reported at the discretion of the physician.
Major bleeding was deﬁned as either intracranial bleeding
or overt bleeding with a decrease in hemoglobin ≥5 g/dL
(≥3.1 mmol/L) or a decrease in hematocrit ≥15%.
Statistical Analysis
Patients were divided into percentiles of NT-proBNP levels at
the time of admission and according to their ZRS. We compared
the predictive accuracy of the ZRS, NT-proBNP, and combined
NT-proBNP/ZRS using receiver operating characteristic (ROC)
curves. A total of 74 patients had missing values on ZRS and 36
on NT-proBNP at baseline (3 patients had missing values on
both). Assuming data were missing at random, a multiple
missing value imputation procedure was applied in which the
values of the NT-proBNP and the values of the elements of the
ZRS were imputed in case they were missing (PROC MI; SAS
version 9.2; SAS Institute Inc., Cary, NC). The ZRS score was
calculated from the individually imputed scores.
The following predictor variables were used for the multiple
imputation: randomization to tiroﬁban or placebo; Killip class;
gender; age; a history of diabetes; smoking; anterior infarction
location; Thrombolysis in Myocardial Infarction (TIMI) post
procedure; ischemic time; heart rate; cardiac troponin baseline;
cardiac troponin 18 to 24 hours; cardiac troponin 72 to
96 hours; NT-proBNP baseline; NT-proBNP 18 to 24 hours; NT-
proBNP 72 to 96 hours; peak CK; cumulative ST deviation 30 to
180 minutes post-PPCI; death after 30 days; vessel disease
(single-vessel disease, 2-vessel disease, 3-vessel disease, or
left main disease); duration of hospital stay; and GFR.
We generated 10 data sets, and the results of all statistical
analyses were pooled across the 10 data sets using the
corresponding pooling procedure in SPSS or SAS. We
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calculated the SD of imputed variables in the baseline table by
multiplying the estimated SE by the square root of N.
The correlation between NT-proBNP and ZRS was calculated
using Spearman’s correlation coefﬁcient. Multivariate Cox’s
regression analysis was used to estimate the inﬂuence of NT-
proBNP and ZRS on 30-day mortality. We adjusted for
randomization (tiroﬁban or placebo), gender, age, renal function
(GFR, mL/min), and body mass index (BMI) in a backward Cox’s
regression with a P value of 0.05 for entry or exit of the variables
in themodel. All statistical analyseswere performed using SPSS
(version 19; SPSS, Inc., Chicago, IL). A 2-sided P value of ≤0.05
was considered statistically signiﬁcant. To perform an analysis
using ZRS and NT-proBNP together, we calculated weighted
scores for each as follows: (b19ZRS)+(b29ln NT-proBNP),
where b1 and b2 denote b coefﬁcients for the ZRS and log NT-
proBNP obtained from the multivariate Cox’s regression model.
Because NT-proBNP was not normally distributed, we used
logarithmically transformed values. We used ROC curves to
deﬁne optimal cut-off values in estimating mortality outcomes
for ZRS, NT-proBNP, and the combination of both.We calculated
the pooled areas under the curve (AUC) and 95% conﬁdence
intervals (CIs) by averaging over the 10 AUCs from the imputed
data sets using Rubin’s rule.17 AUCs were compared in SAS
using PROC Logistic, and the results were pooled across
imputations using Rubin’s rule in order to obtain Wald statistics
and corresponding P values. In Rubin’s rule, the overall estimate
is the average of the individual estimates, and the overall SE is a
function of the within-imputation variance and the between-
imputation variance. The cut-off scores were obtained from the
mean scores across the 10 data sets, which gave the highest
speciﬁcity in combination with 100% sensitivity (e.g., zero
mortality).
In order to calibrate the prediction models, we used logistic
regression models. The raw scores of ZRS and NT-proBNP
separately, ZRS and NT-proBNP together, and the linear
combination of ZRS and NT-proBNP, respectively, were
entered into a logistic regression model with 30-day mortality
as the dependent variable. This was done for each of the
imputed data sets using the pooling procedure in SPSS.
Because we have 10 imputed data sets, this gives 10 P values
per analysis. If a P value is small, this is indicative of a lack of
ﬁt of the model. All statistical analyses were performed using
SPSS (version 19) or SAS (version 9.2).
Results
During the study period, 984 patients were admitted with the
diagnosis of STEMI. A total of 861 patients underwent PPCI.
Baseline characteristics of the whole study population have
been reported previously.15 Thirty-day follow-up was present
in 845 patients, of whom 738 had a valid value for both the
ZRS and baseline NT-proBNP. Based on analysis with
Figure 1. Zwolle Risk Score (A) and relative risk (RR) of 30-day mortality for each score (B). CI
indicates conﬁdence interval; STEMI, ST-elevation myocardial infarction; TIMI, Thrombolysis in
Myocardial Infarction.
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imputation of missing data, the ZRS was calculated from
baseline characteristics at presentation and ranged from 0 to
15 points (meanSD of 2.342.14 points). Of the 845
patients, 679 (80%) were in the very-low-ZRS group (previ-
ously deﬁned as ZRS ≤3). The baseline NT-proBNP values in
the total cohort ranged from 9 to 33 927 pg/mL (meanSD
of 5991883), with a median of 138 pg/mL. Median time
from onset of ischemic symptoms to PPCI was 167 minutes
(meanSD of 238252 minutes). The 25th and 75th
percentile values of NT-proBNP were 60 and 355 pg/mL,
respectively. In Table 1, baseline characteristics according to
the NT-proBNP percentiles are given for patients below and
above the 60th percentile of NT-proBNP values (NT-proBNP
value=198). We chose this cut-off point because all fatal
cases had an NT-proBNP value above the 60th percentile. In
comparison to the lower percentiles, patients above the 60th
percentile were older and more often had diabetes, HTN, a
history of previous angina, and a history of previous MI. In
addition, patients with an NT-proBNP above the 60th percen-
tile had a higher SBP, higher Killip class, higher hemoglobin
level, higher levels of troponin, and a higher ZRS.
At 30 days of follow-up, 21 patients had died. Mortality in
patients with ZRS <6 was signiﬁcantly lower, in comparison
with those with ZRS ≥6 (1.1% vs. 28.6%; P<0.001). Among
the patients with ZRS ≤3 (previously deﬁned as a very-low-
risk group), 30-day mortality was 1.0% (0.1% at 2 days and
0.6% between 2 and 10 days). In patients with NT-proBNP
levels below the 90th percentile, mortality was signiﬁcantly
lower, in comparison with NT-proBNP levels above the 90th
percentile (0.7% vs. 19.0%; P<0.001). In the 21 mortality
cases, median NT-proBNP was 2171 pg/mL (ranging from
213 to 33 927 pg/mL; interquartile range, 1512 to 3620).
We found a signiﬁcant correlation between ZRS and NT-
proBNP (Spearman’s correlation of 0.419; P<0.001). In
Figure 2, 30-day mortality by quartiles of NT-proBNP and the
ZRS is depicted. In uni- and multivariate analysis, both
baseline NT-proBNP and ZRS were strongly predictive for 30-
day mortality. After adjustment for renal function, BMI (kg/
m2), gender, age, and randomization to tiroﬁban or placebo,
the main results of the multivariate analysis did not differ
from the univariate results.
Predictive Accuracy for 30-Day Mortality of ZRS,
Baseline NT-proBNP, and Combined Use
We compared predictive accuracy for 30-day mortality of
the ZRS, baseline NT-proBNP, and combined use of baseline
NT-proBNP/ZRS by means of ROC curves (Figure 3). The
Table 1. Baseline Characteristics of the Included Patients in the Imputed Data Set (n=845) According to the 60th Percentile of
Baseline NT-proBNP
Variable 0 to 60th Percentile (N=507) 60th to 100th Percentile (N=338) P Value
Age (y), meanSD 58.6610.54 67.0211.13 <0.001
Male gender 427/507 (84.2%) 215/338 (63.6%) <0.001
Current smoking 272/506 (53.8%) 137/336 (40.8%) <0.001
Diabetes mellitus 37/506 (7.3%) 53/338 (15.7%) <0.001
Hypertension 129/507 (25.4%) 153/338 (45.3%) <0.001
Hypercholesterolemia 121/506 (23.9%) 101/338 (29.9%) 0.054
Family history 211/503 (41.9%) 129/335 (38.5%) 0.320
Previous angina 42/505 (8.3%) 62/336 (18.5%) <0.001
Previous MI 30/506 (5.9%) 39/337 (11.6%) 0.003
Previous PTCA 35/507 (6.9%) 35/338 (10.4%) 0.075
Previous CABG 7/507 (1.4%) 5/338 (1.5%) >0.99
Previous CVA 7/507 (1.4%) 8/338 (2.4%) 0.288
Systolic blood pressure, meanSD 128.0322.15 134.7026.52 <0.001
Diastolic blood pressure, meanSD 76.3414.19 76.9216.22 0.588
Killip class >I 15/507 (3.0%) 26/338 (7.7%) 0.002
Hemoglobin (mmol/L), meanSD 9.314.12 9.7610.13 0.001
Troponin (lg/L), meanSD 0.170.63 0.681.77 <0.001
Zwolle Risk Score, meanSD 1.761.57 3.212.53 <0.001
All values are denoted as meanSD or absolute numbers and their percentages of the total group, where appropriate. CABG indicates coronary artery bypass grafting;
CVA, cerebrovascular accident; MI, myocardial infarction; NT-proBNP, N-terminal pro–brain natriuretic peptide; PTCA, percutaneous transluminal coronary angioplasty.
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weighted linear combination of baseline NT-proBNP and ZRS,
with the weights obtained from the multivariate Cox’s
regression model, demonstrated the best discriminatory
accuracy in predicting 30-day mortality, with an AUC of
0.94 (95% CI=0.90 to 0.99). Interestingly, the AUC for
baseline NT-proBNP was larger than the AUC for the ZRS
(0.91 [95% CI=0.86 to 0.96] and 0.87 [95% CI=0.79 to 0.95],
respectively, although the difference was not signiﬁcant;
P=0.34). The AUC for the weighted linear combination of
ZRS/NT-proBNP was higher, when compared with ZRS (0.94
versus 0.87 [95% CI=0.79 to 0.95]; P=0.023), and when
compared with NT-proBNP (0.94 versus 0.91 [95% CI=0.86 to
0.96]; P=0.028). The results of the calibration of the models
were good: The chi-square for the Hosmer and Lemeshow’s
goodness-of-ﬁt test was not signiﬁcant, with all P values
greater than 10%.
When we excluded the 110 patients with imputed values,
the results were comparable to the results of the imputed
data set. The AUC for ZRS was 0.84 (95% CI=0.75 to 0.94), as
compared to AUC=0.87 (95% CI=0.79 to 0.95) in the imputed
data set. The AUC for NT-proBNP was 0.92 (95% CI=0.87 to
0.97), as compared to AUC=0.91 (95% CI=0.86 to 0.96) in the
imputed data set, and AUC for the combination of ZRS and
NT-proBNP was 0.94 (95% CI=0.89 to 0.99), as compared to
AUC=0.94 (95% CI=0.94 to 0.99) in the imputed data set.
Subsequently, we determined optimal predictive values for
ZRS and NT-proBNP and the serial combination of the 2 tests,
based on 100% sensitivity (and thus 100% survival), with the
aim to identify a large group low-risk patients suitable for very
early discharge. In Table 2, cut-off values with optimal predic-
tive accuracy are given. It is shown that NT-proBNP <200 pg/
mL was able to classify 60% of the study population as very low
risk, with zeromortality. In a serial test combination of both ZRS
and NT-proBNP, this was as high as 68%.
Figure 2. Thirty-day mortality (%) by quartiles of NT-proBNP and the Zwolle Risk Score in ST-elevation
myocardial infarction patients after primary percutaneous intervention. NT-proBNP indicates N-terminal
pro–brain natriuretic peptide.
Figure 3. ROCcurves ofNT-proBNPand the Zwolle Risk Score (ZRS)
in assessing 30-daymortality after primary percutaneous intervention
in ST-elevation myocardial infarction patients. AUC indicates area
under the curve; CI, conﬁdence interval; NT-proBNP, N-terminal pro–
brain natriuretic peptide; ROC, receiver operating characteristic.
DOI: 10.1161/JAHA.114.001089 Journal of the American Heart Association 5















Based on this serial test combination, we created a
decision rule implying that low-risk patients, eligible for early
discharge, are those with ZRS <2 or baseline NT-proBNP
<200 pg/mL.
Feasibility and Safety of Early Discharge in Low-
Risk Patients According to the Decision Rule
MACEs within 2 days after admission occurred signiﬁcantly
less frequently in low-risk patients than in the higher-risk
group (32 [5.6%] of 542 vs. 29 [10.7%] of 271; P=0.007).
Major bleeding occurred in 8 versus 6 patients, respec-
tively (1.4% vs. 2.2%; P=0.39). Of the 32 low-risk patients
experiencing MACEs within 2 days after PPCI, 13 (40.6%) had
RMI and/or target vessel revascularization, and 19 (59.4%)
had VT resulting in VF in 1 patient. Patients experiencing
MACEs, major bleeding, or early malignant ventricular
arrhythmia, totaling 37 patients, would be excluded for
potential early discharge. Thus, 538 patients would have
been eligible for very early discharge at 48 hours after PPCI.
This accounts for 64% of the study population. Between
48 hours and 10 days after PPCI, 1.7% experienced an
adverse event. MACEs occurred in 7 (1.3%) patients, and
major bleeding occurred in 3 (0.6%). In 1 patient, both events
occurred. Therefore, 9 (1.7%) readmissions within 10 days
after PPCI would have been expected.
Of the patients with MACEs, 2 developed a malignant
cardiac arrhythmia requiring cardioversion or deﬁbrillation (1
patient at day 5 and the other patient at day 8 after PPCI).
Because these events would have been potentially lethal in an
outpatient setting, we looked at these patients in detail and
noticed severe noncardiac comorbidity before VT/VF
occurred in 1 patient. The other patient, who was in a clinical
good condition, had unexpected VF without signs of RMI or
HF, despite low ZRS1 and baseline NT-proBNP (20 pg/mL)
and a left ventricular ejection fraction >35%. This patient was
discharged after placement of an implantable cardioverter
deﬁbrillator.
MACEs or major bleeding later than 10 days after PPCI
occurred in 5 (0.9%) of the low-risk patients, but these events
probably could not have been prevented by initially longer
hospitalization. In conclusion, based on the occurrence of
MACEs and major bleeding, 538 patients (64% of the study
population) could have been discharged 48 hours after PPCI,
without mortality, and with low frequency of MACEs (1.3% of
low-risk patients eligible for very early discharge) and/or
major bleeding (0.6% of low-risk patients eligible for very early
discharge; see Figure 4).
Discussion
Our study reveals that baseline NT-proBNP values predict 30-
day mortality in patients with STEMI, treated with PPCI
independently and even more strongly than ZRS alone.
However, optimum predictive value was reached by a serial
test combination, where NT-proBNP (<200 pg/mL) or ZRS
(<2) were able to identify a large group of patients (68% of the
study population), with zero mortality at 30-day follow-up.
Table 2. Cut-off Values for ZRS, NT-proBNP, and Combination of ZRS/NT-proBNP
Cut-off Value Sensitivity Speciﬁcity (95% CI)
ZRS <2 1.00 0.39 (0.35 to 0.42)
NT-proBNP <200 pg/mL 1.00 0.62 (0.58 to 0.65)
Combination (serial) ZRS <2
or
NT-proBNP <200 pg/mL
1.00 0.70 (0.67 to 0.73)
P values between speciﬁcities. ZRS–NT-proBNP: v2=113.65, df=2, P<0.001; ZRS–combination: v2=256, df=2, P<0.001; NT-proBNP–combination: v2=65, df=2, P<0.001. CI indicates
conﬁdence interval; NT-proBNP, N-terminal pro–brain natriuretic peptide; ZRS, Zwolle Risk Score.
Figure 4. Feasibility of early discharge in 845 PPCI patients
based on ZRS <2 or NT-proBNP <200 pg/mL. MACE indicates
major adverse cardiac events; NT-proBNP, N-terminal pro–brain
natriuretic peptide; PPCI, primary percutaneous coronary interven-
tion; ZRS, Zwolle Risk Score.
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Approximately 64% of the patients in our population would
probably have been eligible for early discharge, with very low
risk of MACEs, bleeding, or malignant ventricular arrhythmia
in the ﬁrst 10 days after admission.
Early Discharge After PPCI
Since the introduction of PPCI, hospitalization duration for
patients with STEMI has been reduced considerably. Present
guidelines now recommend that it is reasonable to discharge
low-risk PPCI patients early (after approximately 72 hours),
providing that rehabilitation and follow-up are properly
arranged.18
Although several studies have shown that early discharge,
particularly within 48 to 72 hours, is safe, feasible, and cost-
effective in uncomplicated PPCI patients,1–6 large, randomized
trials, applying a structured risk strategy prospectively, are
still scarce.
Traditionally, STEMI has been associated with severe
cardiac complications, such as HF, malignant ventricular
arrhythmias, mechanical complications, and, of course, rein-
farction resulting from target segment-related reocclusion or
acute stent thrombosis. In addition, several noncardiac com-
plications, such as severe (groin) bleeding, thromboembolic
complications, or contrast agent-mediated nephropathy, may
occur. The possible occurrence of any of the complications
mentioned above necessitates close monitoring at a coronary
care unit for the ﬁrst 24 to 48 hours of admission. In this
setting, efforts to assess the moment and safety of discharge
are often postponed until the moment that the patient can be
moved to the cardiology ward.
Risk Stratiﬁcation
In the current PPCI era, several risk strategies to identify
STEMI patients eligible for early discharge have been
proposed.1,5,7 The validated and accepted ZRS incorporates
procedural factors and baseline clinical patients characteris-
tics, without the use of time-consuming imaging modalities.
This relatively simple tool was efﬁcient in identifying 74% of
the PPCI patients at a very low mortality risk (0.2%) within 2 to
10 days. Approximately 61% of these patients would be
eligible for discharge at 48 to 72 hours.7 In our study,
baseline NT-proBNP was also strongly predictive for 30-day
mortality, with a higher hazard ratio than the ZRS in
multivariate analysis. Moreover, baseline NT-proBNP had a
highly predictive accuracy, with an AUC higher (although not
reaching signiﬁcance) than for the ZRS. Previous studies
already suggested that, in STEMI patients, NT-proBNP, drawn
within 24 hours of the onset of chest pain, is more accurate in
predicting mortality at 9 months than the Thrombolysis in
Myocardial Infarction (TIMI) risk score.12 Even the ﬁnal PCI
result, in terms of TIMI ﬂow and occurrence of the no-reﬂow
phenomenon, could be predicted by baseline levels of BNP or
NT-proBNP.19,20
In contrast with our previous report,7 we did not accept
any mortality when deﬁning cut-off values, given that mortality
is unacceptable when searching for shortening of hospital-
ization duration. Furthermore, we found a slightly higher
mortality rate between 2 and 10 days (0.6% vs. 0.2%) for ZRS
≤3. We therefore set the cut-off level at a ZRS of <2. None of
the fatal cases in the study population had low baseline NT-
proBNP (all >200 pg/mL), and the mean NT-proBNP for fatal
cases was as high as 4606 pg/mL.
At present, it has been suggested that, in just 30 to 40% of
low-risk PPCI patients, discharge within 4 days is really
effectuated.21,22 This may be improved by an additional
simple baseline NT-proBNP determination. Given our study
results and the fact that biomarkers are more widely
implemented at present, one could question whether ZRS
could be replaced by simple baseline NT-proBNP assessment.
Alternatively, risk stratiﬁcation could be optimized by the
combination of ZRS and NT-proBNP, and a larger group of
patients could be targeted for early and safe discharge, as we
have shown in our results.
Safety Issue
Since the introduction of the ZRS, PPCI techniques and
accompanying periprocedural pharmacological treatment
have been further improved. This has led to a decrease of
ischemic time, higher rates of TIMI III ﬂow before and after
PPCI, improvement of myocardial blush grades,15,23,24 and a
decrease of major bleeding.25 As a consequence, more
patients will be potentially eligible for leaving the hospital
safely, at an early stage.
Although the risk of mortality is an important factor in
the identiﬁcation of PPCI patients, when assessing for
eligibility for early discharge, nonfatal MACEs, major
bleeding, and malignant ventricular arrhythmias are condi-
tions to be accounted for. This diversity of contraindica-
tions can neither be predicted by ZRS nor by baseline
NT-proBNP, but as we have shown, the frequencies of
MACEs and major bleeding are very low in patients with
baseline NT-proBNP <200 pg/mL or ZRS <2. Moreover,
these simple cut-off values could facilitate early discharge
of a large group of patients, at the cost of only few
readmissions.
Limitations
First of all, the sample size for a study of this sort is relatively
small as well as the number of deaths. These small numbers
may limit the strength of the conclusions.
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Moreover, several limitations in our methods have to be
noted: Although, in every patient, baseline NT-proBNP values
were assessed by protocol, the ZRS was calculated afterward.
All patients and outcome measures, however, were monitored
longitudinally. NT-proBNP levels were drawn at variable
periods after onset of symptoms. This variability is accounted
for by the ZRS, which is partially based on ischemic time.
Based on the exclusion criteria, patients with higher Killip
class, elderly patients, and young women were not included in
the study.
We imputed missing values in order to have either a
complete ZRS (74 patients) or NT-proBNP (36 patients). The
reason for this was that when we would exclude the patients
with a missing value on ZRS and/or NT-proBNP, we would
miss 4 of 21 cases of death. When we excluded the 110
patients with imputed values, the results were comparable to
the results of the imputed data set.
Although we succeeded in demonstrating the predictive
accuracy and additional value of the assessment of baseline
NT-proBNP values, we did not effectuate hospital discharge
after 48 hours. Also, we did not study the effect of real
hospital length of stay on 30-day mortality, although most
patients (80%) were at low mortality risk according to the ZRS.
Prospective validation is therefore warranted in future
studies, using the presently deﬁned cut-off values. Further-
more, the predictive value of consecutive NT-proBNP levels,
during and after PPCI, should be evaluated in order to optimize
early discharge policy in successfully treated STEMI patients.
Conclusion
Baseline NT-proBNP is highly predictive for short-term mor-
tality in PPCI patients and identiﬁes a large group (64%) of
very-low-risk patients (i.e., zero mortality at 30 days). These
patients are potentially eligible for early discharge (48 hours
after successful PPCI), with very low rate of nonfatal MACE
and major bleeding up to 10 days after admission. Optimal
predictive accuracy is reached by the combination of both
ZRS <2 and baseline NT-proBNP ≤200 pg/mL.
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